{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=i-scan&page=5", "query": { "intervention": "i-scan", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 682, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=i-scan&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=i-scan&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T21:05:52.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03914846", "title": "Ultrasound in Diagnosing Patients With Skin Lesions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Skin Lesion" ], "interventions": [ { "name": "Ultrasound", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2019-04-29", "completion_date": "2022-10-20", "has_results": false, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914846" }, { "nct_id": "NCT05773274", "title": "Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Digestive System Neuroendocrine Tumor G2", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Digestive System Neuroendocrine Tumor G2" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-01-12", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05773274" }, { "nct_id": "NCT05031910", "title": "Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2022-02-04", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05031910" }, { "nct_id": "NCT07417488", "title": "GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Ad5.F35-hGUCY2C-PADRE vaccine", "type": "BIOLOGICAL" }, { "name": "Lm-GUCY2C vaccine", "type": "BIOLOGICAL" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-04-21", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07417488" }, { "nct_id": "NCT06712810", "title": "Q702 for the Treatment of Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Histiocytic Sarcoma", "Malignant Histiocytosis", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Follicular Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelofibrosis", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Erdheim-Chester Disease", "Refractory Follicular Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Myelodysplastic Syndrome", "Refractory Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Rosai-Dorfman-Destombes Disease", "Primary Central Nervous System Lymphoma", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Erdheim-Chester Disease", "Recurrent Fibroblastic Reticular Cell Sarcoma", "Recurrent Histiocytic Sarcoma", "Recurrent Interdigitating Dendritic Cell Sarcoma", "Recurrent Rosai-Dorfman-Destombes Disease", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Fibroblastic Reticular Cell Sarcoma", "Refractory Histiocytic Sarcoma", "Refractory Interdigitating Dendritic Cell Sarcoma", "Refractory Rosai-Dorfman-Destombes Disease" ], "interventions": [ { "name": "Axl/Mer/CSF1R Inhibitor Q702", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2025-08-27", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712810" }, { "nct_id": "NCT06682442", "title": "Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nasopharyngeal Carcinoma", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Nasopharyngeal Cancer", "Nasopharyngeal Cancer Stage" ], "interventions": [ { "name": "Intensity-Modulated Radiation Therapy (IMRT)", "type": "RADIATION" }, { "name": "Radiographic Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2025-03-18", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682442" }, { "nct_id": "NCT02079662", "title": "The Role of Lifestyle Factors in Breast Cancer-Related Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Behavioral, Psychological or Informational Intervention", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Cognitive Intervention", "type": "OTHER" }, { "name": "Computer-Assisted Intervention", "type": "OTHER" }, { "name": "Counseling", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 110, "start_date": "2013-06-13", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02079662" }, { "nct_id": "NCT02194738", "title": "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage II Lung Non-Small Cell Cancer AJCC v7", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7458, "start_date": "2014-09-26", "completion_date": "2027-09-21", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 1655, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194738" }, { "nct_id": "NCT02137252", "title": "Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Breast Cancer (Stage I-III)", "Ductal Carcinoma in Situ", "Lobular Carcinoma in Situ", "Lobular Carcinoma", "Fatigue Related to Cancer Treatment" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Sugar Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-05", "completion_date": "2015-08-01", "has_results": true, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02137252" }, { "nct_id": "NCT06169215", "title": "Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Daratumumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 58, "start_date": "2024-07-23", "completion_date": "2027-09-23", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-29T21:05:52.805Z", "location_count": 27, "location_summary": "Irvine, California • Laguna Hills, California • Orange, California + 22 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06169215" } ] }